- Novavax said it expects to finalize an agreement that would see it begin to supply Canada with doses “as early as the second quarter of 2021,” the company said.
- The company’s vaccine, calledNVX-CoV2373, is currently in phase two trials.
- Novavax has previously said it could begin late-stage trials as early as October.
American vaccine developer Novavax announced Monday that it’s reached an agreement in principle with Canada to supply 76 million doses of its experimental coronavirus vaccine to the country.
The company said it expects to finalize an agreement to supply Canada with doses “as early as the second quarter of 2021.” The agreement is contingent on the vaccine getting a license fromHealth Canada, the company said.
Shares of Novavax rose nearly 2% in early morning trading on the news.
The company’s vaccine, calledNVX-CoV2373…
View original post 168 more words